Ketamine abuse: Another side of the miracle drug (A case report)
Bouchra Hallab, Khansaa Layoussifi, El Yazaji Meriem
Casablanca Addictology Centre at the University Hospital Centre Ibn ROCHD. Morocco
Laboratory of clinical neuroscience and mental health. Hassan II University.
Faculty of Medicine and Pharmacy of Casablanca.
*Corresponding author
*Bouchra Hallab, Casablanca Addictology Centre at the University Hospital Centre Ibn ROCHD. Morocco
DOI: 10.55920/JCRMHS.2023.04.001146
- M. S. Kurdi, K. A. Theerth, et R. S. Deva, « Ketamine: Current applications in anesthesia, pain, and critical care », Anesth. Essays Res., vol. 8, no 3, p. 283‑290, 2014, doi: 10.4103/0259-1162.143110.
- A. Nowacka et M. Borczyk, « Ketamine applications beyond anesthesia - A literature review », Eur. J. Pharmacol., vol. 860, p. 172547, oct. 2019, doi: 10.1016/j.ejphar.2019.172547.
- W.-Y. Chen, M.-C. Huang, et S.-K. Lin, « Gender differences in subjective discontinuation symptoms associated with ketamine use », Subst. Abuse Treat. Prev. Policy, vol. 9, no 1, p. 39, sept. 2014, doi: 10.1186/1747-597X-9-39.
- G. Bokor et P. D. Anderson, « Ketamine: an update on its abuse », J. Pharm. Pract., vol. 27, no 6, p. 582‑586, déc. 2014, doi: 10.1177/0897190014525754.
- B. Le Daré, R. Pelletier, I. Morel, et T. Gicquel, « [History of Ketamine: An ancient molecule that is still popular today] », Ann. Pharm. Fr., vol. 80, no 1, p. 1‑8, janv. 2022, doi: 10.1016/j.pharma.2021.04.005.
- J. Kim, T. Farchione, A. Potter, Q. Chen, et R. Temple, « Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class », N. Engl. J. Med., vol. 381, no 1, p. 1‑4, juill. 2019, doi: 10.1056/NEJMp1903305.
- L. Li et P. E. Vlisides, « Ketamine: 50 Years of Modulating the Mind », Front. Hum. Neurosci., vol. 10, p. 612, 2016, doi: 10.3389/fnhum.2016.00612.
- Y. Liu, D. Lin, B. Wu, et W. Zhou, « Ketamine abuse potential and use disorder », Brain Res. Bull., vol. 126, no Pt 1, p. 68‑73, sept. 2016, doi: 10.1016/j.brainresbull.2016.05.016.
- J. Bonaventura et al., « Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability », Mol. Psychiatry, vol. 26, no 11, p. 6704‑6722, nov. 2021, doi: 10.1038/s41380-021-01093-2.
- L. Vines et al., « Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions », Intell. Med., vol. 2, no 2, p. 61‑68, mai 2022, doi: 10.1016/j.imed.2022.03.001.
- J. J. Palamar, C. Rutherford, et K. M. Keyes, « Trends in Ketamine Use, Exposures, and Seizures in the United States up to 2019 », Am. J. Public Health, vol. 111, no 11, p. 2046‑2049, nov. 2021, doi: 10.2105/AJPH.2021.306486.
- P. Dillon, J. Copeland, et K. Jansen, « Patterns of use and harms associated with non-medical ketamine use », Drug Alcohol Depend., vol. 69, no 1, p. 23‑28, janv. 2003, doi: 10.1016/s0376-8716(02)00243-0.
- G. Salvadore et J. B. Singh, « Ketamine as a fast acting antidepressant: current knowledge and open questions », CNS Neurosci. Ther., vol. 19, no 6, p. 428‑436, juin 2013, doi: 10.1111/cns.12103.
- H.-J. Liang, G. S. Ungvari, T. S.-H. Lee, et W.-K. Tang, « Ketamine Addiction », Dual Diagn. Open Access, vol. 3, no 1, p. 0‑0, doi: 10.21767/2472-5048.100037.
- J. McCambridge, A. Winstock, N. Hunt, et L. Mitcheson, « 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users », Eur. Addict. Res., vol. 13, no 1, p. 57‑64, 2007, doi: 10.1159/000095816.
- A. J. Schmidt et al., « Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS) », Int. J. Drug Policy, vol. 38, p. 4‑12, déc. 2016, doi: 10.1016/j.drugpo.2016.09.007.
- K. I. Morley, M. T. Lynskey, P. Moran, R. Borschmann, et A. R. Winstock, « Polysubstance use, mental health and high-risk behaviours: Results from the 2012 Global Drug Survey », Drug Alcohol Rev., vol. 34, no 4, p. 427‑437, juill. 2015, doi: 10.1111/dar.12263.
- T. T. Le et al., « The abuse liability of ketamine: A scoping review of preclinical and clinical studies », J. Psychiatr. Res., vol. 151, p. 476‑496, juill. 2022, doi: 10.1016/j.jpsychires.2022.04.035.
- L. Li et P. E. Vlisides, « Ketamine: 50 Years of Modulating the Mind », Front. Hum. Neurosci., vol. 10, p. 612, 2016, doi: 10.3389/fnhum.2016.00612.
- C. Reynaud-Maurupt, P.-Y. Bello, S. Akoka, et A. Toufik, « Characteristics and behaviors of ketamine users in France in 2003 », J. Psychoactive Drugs, vol. 39, p. 1‑11, 2007, doi: 10.1080/02791072.2007.10399859.
- K. Hashimoto, « Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine », Biochem. Pharmacol., vol. 177, p. 113935, juill. 2020, doi: 10.1016/j.bcp.2020.113935.
- S. M. Pai, J.-M. Gries, et ACCP Public Policy Committee, « Off-Label Use of Ketamine: A Challenging Drug Treatment Delivery Model With an Inherently Unfavorable Risk-Benefit Profile », J. Clin. Pharmacol., vol. 62, no 1, p. 10‑13, janv. 2022, doi: 10.1002/jcph.1983.
- A. Wilkowska, M. S. Wiglusz, K. Jakuszkowiak-Wojten, et W. J. Cubała, « Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review », Cells, vol. 11, no 4, p. 645, févr. 2022, doi: 10.3390/cells11040645.
- G. C. Britt et E. F. McCance-Katz, « A brief overview of the clinical pharmacology of “club drugs” », Subst. Use Misuse, vol. 40, no 9‑10, p. 1189‑1201, 2005, doi: 10.1081/JA-200066730.
- L. K. Wilkins, T. A. Girard, et J. A. Cheyne, « Anomalous bodily-self experiences among recreational ketamine users », Cognit. Neuropsychiatry, vol. 17, no 5, p. 415‑430, sept. 2012, doi: 10.1080/13546805.2012.663162.
- G. Corssen et E. F. Domino, « Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581 », Anesth. Analg., vol. 45, no 1, p. 29‑40, 1966.
- R. J. Strayer et L. S. Nelson, « Adverse events associated with ketamine for procedural sedation in adults », Am. J. Emerg. Med., vol. 26, no 9, p. 985‑1028, nov. 2008, doi: 10.1016/j.ajem.2007.12.005.
- T.-H. Tsai et al., « Ketamine-associated bladder dysfunction », Int. J. Urol. Off. J. Jpn. Urol. Assoc., vol. 16, no 10, p. 826‑829, oct. 2009, doi: 10.1111/j.1442-2042.2009.02361.x.
- A. Wong, N. J. Benedict, M. J. Armahizer, et S. L. Kane-Gill, « Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome », Ann. Pharmacother., vol. 49, no 1, p. 14‑19, janv. 2015, doi: 10.1177/1060028014555859.
- W.-L. Yu et al., « Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings », Abdom. Imaging, vol. 39, no 6, p. 1241‑1246, déc. 2014, doi: 10.1007/s00261-014-0173-2.
- Z. Walsh et al., « Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review », BJPsych Open, vol. 8, no 1, p. e19, déc. 2021, doi: 10.1192/bjo.2021.1061.
- M.-C. Huang, L.-Y. Chen, C.-K. Chen, et S.-K. Lin, « Potential benefit of lamotrigine in managing ketamine use disorder », Med. Hypotheses, vol. 87, p. 97‑100, févr. 2016, doi: 10.1016/j.mehy.2015.11.011.
- J. Copeland et P. Dillon, « The health and psycho-social consequences of ketamine use », Int. J. Drug Policy, vol. 16, no 2, p. 122, 2005.